➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Johnson and Johnson
Moodys
AstraZeneca

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for MYK-461


Email this page to a colleague

« Back to Dashboard

What is the drug development status for MYK-461?

MYK-461 is an investigational drug.

There have been 11 clinical trials for MYK-461. The most recent clinical trial was a Phase 1 trial, which was initiated on May 29th 2018.

The most common disease conditions in clinical trials are Cardiomyopathies, Hypertrophy, and Cardiomyopathy, Hypertrophic. The leading clinical trial sponsors are MyoKardia, Inc. and [disabled in preview].

There are two US patents protecting this investigational drug and forty-one international patents.

Recent Clinical Trials for MYK-461
TitleSponsorPhase
Exploratory Study of MYK-491 in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic VariantsMyoKardia, Inc.Phase 2
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMMyoKardia, Inc.Phase 2/Phase 3
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyMyoKardia, Inc.Phase 3

See all MYK-461 clinical trials

Clinical Trial Summary for MYK-461

Top disease conditions for MYK-461
Top clinical trial sponsors for MYK-461

See all MYK-461 clinical trials

US Patents for MYK-461

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MYK-461 ⤷  Try it Free Pyrimidinedione compounds Myokardia, Inc. (South San Francisco, CA) ⤷  Try it Free
MYK-461 ⤷  Try it Free Pyrimidinedione compounds MYOKARDIA, INC. (South San Francisco, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MYK-461

Drugname Country Document Number Estimated Expiration Related US Patent
MYK-461 Australia AU2014281408 2033-06-21 ⤷  Try it Free
MYK-461 Australia AU2018264088 2033-06-21 ⤷  Try it Free
MYK-461 Australia AU2020204271 2033-06-21 ⤷  Try it Free
MYK-461 Brazil BR112015031864 2033-06-21 ⤷  Try it Free
MYK-461 Canada CA2915967 2033-06-21 ⤷  Try it Free
MYK-461 Chile CL2015003689 2033-06-21 ⤷  Try it Free
MYK-461 China CN105473576 2033-06-21 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
Merck
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.